- Home
- HSCS vs WINT Comparison
HSCS vs WINT Comparison
Compare HSCS & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- WINT
- Stock Information
- Founded
- HSCS 2007
- WINT 1992
- Country
- HSCS United States
- WINT United States
- Employees
- HSCS N/A
- WINT N/A
- Industry
- HSCS Medical Specialities
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSCS Health Care
- WINT Health Care
- Exchange
- HSCS Nasdaq
- WINT Nasdaq
- Market Cap
- HSCS 3.7M
- WINT 3.6M
- IPO Year
- HSCS 2022
- WINT 1995
- Fundamental
- Price
- HSCS $3.56
- WINT $0.75
- Analyst Decision
- HSCS Strong Buy
- WINT Hold
- Analyst Count
- HSCS 2
- WINT 1
- Target Price
- HSCS $13.00
- WINT $350.00
- AVG Volume (30 Days)
- HSCS 19.7K
- WINT 211.6K
- Earning Date
- HSCS 07-28-2025
- WINT 05-16-2025
- Dividend Yield
- HSCS N/A
- WINT N/A
- EPS Growth
- HSCS N/A
- WINT N/A
- EPS
- HSCS N/A
- WINT N/A
- Revenue
- HSCS N/A
- WINT N/A
- Revenue This Year
- HSCS N/A
- WINT N/A
- Revenue Next Year
- HSCS N/A
- WINT N/A
- P/E Ratio
- HSCS N/A
- WINT N/A
- Revenue Growth
- HSCS 261.17
- WINT N/A
- 52 Week Low
- HSCS $2.36
- WINT $0.73
- 52 Week High
- HSCS $7.57
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- HSCS 48.30
- WINT 30.78
- Support Level
- HSCS $3.71
- WINT $0.73
- Resistance Level
- HSCS $4.54
- WINT $0.85
- Average True Range (ATR)
- HSCS 0.38
- WINT 0.06
- MACD
- HSCS -0.04
- WINT 0.03
- Stochastic Oscillator
- HSCS 22.27
- WINT 18.73
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.